Annual CFO
-$23.52 M
+$430.00 K+1.80%
31 December 2023
Summary:
Enlivex Therapeutics annual cash flow from operations is currently -$23.52 million, with the most recent change of +$430.00 thousand (+1.80%) on 31 December 2023. During the last 3 years, it has fallen by -$12.52 million (-113.71%). ENLV annual CFO is now -15687.25% below its all-time high of -$149.00 thousand, reached on 31 December 2012.ENLV Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.80 M
+$2.71 M+60.16%
30 June 2024
Summary:
Enlivex Therapeutics quarterly cash flow from operations is currently -$1.80 million, with the most recent change of +$2.71 million (+60.16%) on 30 June 2024. Over the past year, it has increased by +$3.64 million (+66.96%). ENLV quarterly CFO is now -151.79% below its all-time high of $3.47 million, reached on 31 December 2017.ENLV Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$17.02 M
+$5.23 M+23.49%
30 June 2024
Summary:
Enlivex Therapeutics TTM cash flow from operations is currently -$17.02 million, with the most recent change of +$5.23 million (+23.49%) on 30 June 2024. Over the past year, it has increased by +$6.04 million (+26.19%). ENLV TTM CFO is now -1350.77% below its all-time high of $1.36 million, reached on 30 September 2018.ENLV TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.8% | +67.0% | +26.2% |
| 3 y3 years | -113.7% | +57.2% | -1.9% |
| 5 y5 years | -644.2% | +12.1% | -164.3% |
ENLV Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -113.7% | +1.8% | at high | +80.6% | -1.9% | +35.7% |
| 5 y | 5 years | -644.2% | +1.8% | -330.7% | +80.6% | -227.8% | +35.7% |
| alltime | all time | <-9999.0% | +1.8% | -151.8% | +80.6% | -1350.8% | +35.7% |
Enlivex Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$1.80 M(-60.2%) | -$17.02 M(-23.5%) |
| Mar 2024 | - | -$4.51 M(-14.5%) | -$22.25 M(-5.4%) |
| Dec 2023 | -$23.52 M(-1.8%) | -$5.28 M(-3.0%) | -$23.52 M(+2.0%) |
| Sept 2023 | - | -$5.44 M(-22.6%) | -$23.06 M(-4.8%) |
| June 2023 | - | -$7.02 M(+21.4%) | -$24.22 M(-8.5%) |
| Mar 2023 | - | -$5.78 M(+20.0%) | -$26.47 M(+10.5%) |
| Dec 2022 | -$23.95 M(+36.5%) | -$4.82 M(-26.9%) | -$23.95 M(-6.9%) |
| Sept 2022 | - | -$6.59 M(-28.9%) | -$25.73 M(+10.3%) |
| June 2022 | - | -$9.27 M(+183.7%) | -$23.33 M(+26.3%) |
| Mar 2022 | - | -$3.27 M(-50.4%) | -$18.47 M(+5.3%) |
| Dec 2021 | -$17.54 M(+59.4%) | -$6.59 M(+56.9%) | -$17.54 M(+5.0%) |
| Sept 2021 | - | -$4.20 M(-4.7%) | -$16.71 M(+12.4%) |
| June 2021 | - | -$4.41 M(+88.5%) | -$14.86 M(+5.2%) |
| Mar 2021 | - | -$2.34 M(-59.4%) | -$14.13 M(+28.3%) |
| Dec 2020 | -$11.01 M(+56.3%) | -$5.76 M(+144.8%) | -$11.01 M(+59.5%) |
| Sept 2020 | - | -$2.35 M(-36.0%) | -$6.90 M(+4.7%) |
| June 2020 | - | -$3.67 M(-571.6%) | -$6.59 M(+26.9%) |
| Mar 2020 | - | $779.00 K(-147.2%) | -$5.19 M(-26.2%) |
| Dec 2019 | -$7.04 M(+122.7%) | -$1.65 M(-19.2%) | -$7.04 M(+9.3%) |
| Sept 2019 | - | -$2.04 M(-10.1%) | -$6.44 M(+26.1%) |
| June 2019 | - | -$2.27 M(+112.8%) | -$5.11 M(+51.8%) |
| Mar 2019 | - | -$1.07 M(+1.6%) | -$3.36 M(+6.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$3.16 M(+37.2%) | -$1.05 M(+47.8%) | -$3.16 M(-332.3%) |
| Sept 2018 | - | -$712.00 K(+34.1%) | $1.36 M(+35.4%) |
| June 2018 | - | -$531.00 K(-38.7%) | $1.00 M(-350.6%) |
| Mar 2018 | - | -$866.00 K(-125.0%) | -$401.00 K(-82.6%) |
| Dec 2017 | -$2.30 M(-85.1%) | $3.47 M(-424.9%) | -$2.30 M(-73.7%) |
| Sept 2017 | - | -$1.07 M(-44.9%) | -$8.75 M(-17.0%) |
| June 2017 | - | -$1.94 M(-30.0%) | -$10.54 M(-26.3%) |
| Mar 2017 | - | -$2.77 M(-6.9%) | -$14.31 M(-7.6%) |
| Dec 2016 | -$15.49 M(+16.9%) | -$2.97 M(+4.0%) | -$15.49 M(-4.1%) |
| Sept 2016 | - | -$2.86 M(-49.9%) | -$16.16 M(-1.9%) |
| June 2016 | - | -$5.70 M(+44.5%) | -$16.46 M(+20.7%) |
| Mar 2016 | - | -$3.95 M(+8.3%) | -$13.64 M(+3.0%) |
| Dec 2015 | -$13.25 M(+200.5%) | -$3.64 M(+15.1%) | -$13.25 M(+19.7%) |
| Sept 2015 | - | -$3.17 M(+9.7%) | -$11.07 M(+15.6%) |
| June 2015 | - | -$2.88 M(-18.8%) | -$9.58 M(+30.2%) |
| Mar 2015 | - | -$3.56 M(+142.2%) | -$7.36 M(+66.9%) |
| Dec 2014 | -$4.41 M(+409.7%) | -$1.47 M(-12.0%) | -$4.41 M(+49.9%) |
| Sept 2014 | - | -$1.67 M(+151.0%) | -$2.94 M(+131.2%) |
| June 2014 | - | -$665.00 K(+9.6%) | -$1.27 M(+109.6%) |
| Mar 2014 | - | -$607.00 K | -$607.00 K |
| Dec 2013 | -$865.00 K(+480.5%) | - | - |
| Dec 2012 | -$149.00 K | - | - |
FAQ
- What is Enlivex Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual CFO year-on-year change?
- What is Enlivex Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly CFO year-on-year change?
- What is Enlivex Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM CFO year-on-year change?
What is Enlivex Therapeutics annual cash flow from operations?
The current annual CFO of ENLV is -$23.52 M
What is the all time high annual CFO for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual cash flow from operations is -$149.00 K
What is Enlivex Therapeutics annual CFO year-on-year change?
Over the past year, ENLV annual cash flow from operations has changed by +$430.00 K (+1.80%)
What is Enlivex Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ENLV is -$1.80 M
What is the all time high quarterly CFO for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly cash flow from operations is $3.47 M
What is Enlivex Therapeutics quarterly CFO year-on-year change?
Over the past year, ENLV quarterly cash flow from operations has changed by +$3.64 M (+66.96%)
What is Enlivex Therapeutics TTM cash flow from operations?
The current TTM CFO of ENLV is -$17.02 M
What is the all time high TTM CFO for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM cash flow from operations is $1.36 M
What is Enlivex Therapeutics TTM CFO year-on-year change?
Over the past year, ENLV TTM cash flow from operations has changed by +$6.04 M (+26.19%)